Stereospecific metabolism of itraconazole by CYP3A4: Dioxolane ring scission of azole antifungals

Drug Metabolism and Disposition

Volumn 40, Issue 3, 2012, Pages 426-435

  Peng, Chi Chi ^a   Shi, Wei ^b   Lutz, Justin D ^a   Kunze, Kent L ^a   Liu, Jun O ^b   Nelson, Wendel L ^a   Isoherranen, Nina ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 2 (1H 1,2,4 TRIAZOL 1 YL)ETHANONE; 1,3 DIOXOLANE; 3' HYDROXYITRACONAZOLE; CYTOCHROME P450 3A4; DRUG METABOLITE; ITRACONAZOLE; KETOITRACONAZOLE; MIDAZOLAM; NORITRACONAZOLE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DISSOCIATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IC 50; IN VIVO STUDY; LIVER MICROSOME; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEREOISOMERISM; STEREOSPECIFICITY;

ANTIFUNGAL AGENTS; AZOLES; BINDING SITES; CATALYTIC DOMAIN; CYTOCHROME P-450 CYP3A; DIOXOLANES; FEMALE; HEME; HUMANS; HYDROXYLATION; IRON; ITRACONAZOLE; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDAZOLAM; STEREOISOMERISM; TRIAZOLES;

EID: 84863163564     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.042739     Document Type: Article

References (18)

1. Chen PJ, Moore T, and Nesnow S (2008) Cytotoxic effects of propiconazole and its metabolites in mouse and human hepatoma cells and primary mouse hepatocytes. Toxicol in Vitro 22:1476-1483.
2. Gillam EM, Baba T, Kim BR, Ohmori S, and Guengerich FP (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys 305:123-131. (Pubitemid 23242002)
3. Haria M, Bryson HM, and Goa KL (1996) Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51:585-620.
4. Heykants J, Michiels M, Meuldermans W, Monbaliu J, Lavrijsen K, Van Peer A, Levron J, Woestenborghs R, and Cauwenbergh G (1987) The pharmacokinetics of itraconazole in animals and man: an overview, in Recent Trends in the Discovery, Development, and Evaluation of Antifungal Agents, pp 223-249, J. R. Prous Science Publishers, Barcelona, Spain.
5. Isoherranen N, Kunze KL, Allen KE, Nelson WL, and Thummel KE (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32:1121-1131. (Pubitemid 39287586)
6. Kunze KL, Nelson WL, Kharasch ED, Thummel KE, and Isoherranen N (2006) Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab Dispos 34:583-590.
7. Lewis JH, Zimmerman HJ, Benson GD, and Ishak KG (1984) Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 86:503-513. (Pubitemid 14154661)
8. Neuvonen PJ, Kantola T, and Kivistö KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332-341. (Pubitemid 28182231)
9. Olkkola KT, Ahonen J, and Neuvonen PJ (1996) The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82:511-516. (Pubitemid 26072953)
10. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239:2379-2385.
11. Pearson J, Dahal UP, Rock D, Peng CC, Schenk JO, Joswig-Jones C, and Jones JP (2011) The kinetic mechanism for cytochrome P450 metabolism of type II binding compounds: evidence supporting direct reduction. Arch Biochem Biophys 511:69-79.
12. Pearson JT, Hill JJ, Swank J, Isoherranen N, Kunze KL, and Atkins WM (2006) Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations. Biochemistry 45:6341-6353. (Pubitemid 43787801)
13. Shaw PM, Hosea NA, Thompson DV, Lenius JM, and Guengerich FP (1997) Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5. Arch Biochem Biophys 348:107-115. (Pubitemid 27514676)
14. Shi W, Nacev BA, Bhat S, and Liu JO (2010) Impact of absolute stereochemistry on the antiangiogenic and antifungal activities of itraconazole. ACS Med Chem Lett 1:155-159.
15. Templeton I, Peng CC, Thummel KE, Davis C, Kunze KL, and Isoherranen N (2010) Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther 88:499-505.
16. Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, and Isoherranen N (2008) Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 83:77-85.
17. Vanden Bossche H, Marichal P, Gorrens J, Coene MC, Willemsens G, Bellens D, Roels I, Moereels H, and Janssen PA (1989) Biochemical approaches to selective antifungal activity. Focus on azole antifungals. Mycoses 32 (Suppl 1):35-52. (Pubitemid 20118614)
18. Wang JL, Chang CH, Young-Xu Y, and Chan KA (2010) Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother 54:2409-2419.